|
|
|
|
Vol. 62, Issue 6, 1373-1384, December 2002
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e
Biotecnologie, Universitá Pisa, Pisa, Italy (M.L.T., D.T., M.M.,
C.M.); Dipartimento di Morfologia Umana e Biologia Applicata,
Universitá Pisa, Pisa, Italy (A.F., V.G.); Dipartimento di
Scienze Farmacologiche, Universitá Milano, Milan, Italy (S.C.,
M.P.A., F.C.); and Molecular Recognition Section, Laboratory of
Bioorganic Chemistry, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland
(K.A.J.)
A3 adenosine receptor activation has been previously
demonstrated to result in both neuroprotective and neurodegenerative effects, depending upon specific pathophysiological conditions. This
dual effect may depend on receptor regulation mechanisms that are able
to change receptor availability and/or function. In the present study,
we investigated desensitization, internalization, and down-regulation
of native A3 adenosine receptors in human astrocytoma cells
after exposure to the agonist
2-chloro-N6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (Cl-IBMECA). Cl-IBMECA induced a concentration-dependent
inhibition of adenylyl cyclase activity with an EC50 value
of 2.9 ± 0.1 nM. The effect was suggested to be mediated by
A3 adenosine receptor subtype by the use of selective
adenosine receptor antagonists. Cell treatment with pertussis toxin
abolished Cl-IBMECA-mediated inhibition of adenylyl cyclase activity,
evidencing an A3 receptor coupling to inhibitory G protein.
Short-term exposure to the agonist Cl-IBMECA (100 nM) caused rapid
receptor desensitization, within 15 min. Agonist-induced
desensitization was accompanied by receptor internalization:
A3 adenosine receptor internalized with rapid kinetics,
within 30 min, after cell exposure to 100 nM Cl-IBMECA. The
localization of A3 adenosine receptors on the plasma
membrane and in intracellular compartments was directly revealed by
immunogold electron microscopy. After desensitization, the removal of
agonist led to the restoration of A3 adenosine receptor
functioning through receptor recycling to the cell surface within 120 min. Prolonged agonist exposure (1-24 h) resulted in a marked
down-regulation of A3 adenosine receptors that reached
21.9 ± 2.88% of control value after 24 h. After
down-regulation, the recovery of receptor functioning was slow (24 h)
and associated with the restoration of receptor levels close to control
values. In conclusion, our results demonstrated that A3
receptors, in astrocytoma cells, are regulated after short- and
long-term agonist exposure.
This article has been cited by other articles:
![]() |
B. Costa, A. Salvetti, L. Rossi, F. Spinetti, A. Lena, B. Chelli, M. Rechichi, E. Da Pozzo, V. Gremigni, and C. Martini Peripheral Benzodiazepine Receptor: Characterization in Human T-Lymphoma Jurkat Cells Mol. Pharmacol., January 1, 2006; 69(1): 37 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Madi, A. Ochaion, L. Rath-Wolfson, S. Bar-Yehuda, A. Erlanger, G. Ohana, A. Harish, O. Merimski, F. Barer, and P. Fishman The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells: Potential Target for Tumor Growth Inhibition Clin. Cancer Res., July 1, 2004; 10(13): 4472 - 4479. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Madi, S. Bar-Yehuda, F. Barer, E. Ardon, A. Ochaion, and P. Fishman A3 Adenosine Receptor Activation in Melanoma Cells: ASSOCIATION BETWEEN RECEPTOR FATE AND TUMOR GROWTH INHIBITION J. Biol. Chem., October 24, 2003; 278(43): 42121 - 42130. [Abstract] [Full Text] [PDF] |
||||